NCT07262268
A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia
Enrolling by Invitation
PHASE1Ages 18–75InterventionalTreatmentBiohaven Therapeutics Ltd.
~5 participants
Updated 2026-04-08 on ClinicalTrials.gov
What's tested:BHV-7000Placebo
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean of the daily average maximum pain intensity scores collected every 2 hours.
Measured over The last 3 weeks of each 4-week crossover treatment period
Conditions
Where it's being run
1 sites across 1 statesConnecticut1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Mean of the daily average maximum pain intensity scores collected every 2 hours.The last 3 weeks of each 4-week crossover treatment period
Participants will be asked to record peak (worst) pain experienced in the previous 2 hours using an 11-point Likert scale (0-10) where 0=no pain and 10=worst possible pain